TickerTalks
Browse all tickers →
TickerTalks›$CNXU
CNCNXU

Conexeu Sciences Inc.

$CNXU·$174M·Biotechnology·Healthcare
$8.31-5.9%1Y-36.4%
Mentions · last 7 days
2026-07-25: 0 posts2026-07-26: 0 posts2026-07-27: 2 posts2026-07-28: 2 posts2026-07-29: 1 posts2026-07-30: 1 posts2026-07-31: 0 posts60%
Price updated 3d ago·X counts updated 3d ago
CNCNXU
$CNXUConexeu Sciences Inc.
$8.31-5.89%6 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $CNXU, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Too early to tellWinding up for a moveAI verdict · as of 2026-07-31

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Conexeu is a preclinical regenerative-biomaterials micro-cap pitching itself as the aesthetics answer to GLP-1-driven volume loss.

Conexeu Sciences (recently renamed from Connexa Sports Technologies) is a preclinical-stage regenerative-biomaterials company developing a CXU collagen injectable platform aimed at aesthetics — specifically the tissue-restoration gap that has opened up as GLP-1 weight-loss drugs cause facial and body volume loss that existing aesthetic injectables weren't designed to address.

What the story actually is:

  • The narrative is a real market opportunity: the GLP-1 boom has genuinely created demand for aesthetic products that restore volume rather than just fill lines — analyst framing of a $2B aesthetics opportunity opening up alongside a $190B weight-loss market is directionally credible, and Conexeu is positioning as a first mover into that gap.
  • Preclinical work is progressing but revenue is zero: the July 7 completion of a 12-month PROOF preclinical study for the CXU collagen injectable platform is a real datapoint, and the company is on the FDA 510(k) pathway — meaning the regulatory path is the medical-device route, not a full biologics NDA, which materially compresses the timeline versus a drug program.
  • The financial picture is opaque: standard P/E, P/S, and margin metrics are all n/a, and the company was recently renamed from a sports-tech company (Connexa) — meaning the underwriting is entirely on the pipeline plus the recent Vancouver R&D facility opening, not on any historical operating record.

The path from here is regulatory — the FDA 510(k) submission acceptance would materially reprice this from 'story stock' to 'medical-device-in-review.' The September 30 quarterly print will be a management-color report. What breaks the setup is a delayed 510(k) submission or a competitive product filing from an established aesthetics player; what extends it is FDA acceptance of the 510(k) submission or a named strategic partnership with an established aesthetics distribution channel.

What to watch: Watch (1) FDA 510(k) submission and any acceptance letter for the CXU collagen injectable, (2) any strategic-partnership announcement with an established aesthetics distributor (which is what turns pipeline into commercial-ready), and (3) the September 30 quarterly print for capital-position and pipeline-timeline updates. A delayed 510(k) or competitive product from an incumbent breaks the setup; an FDA acceptance letter or named distribution partner extends it.

On the calendar: 2026-09-30 — Q2 earnings

sentiment missingfinancials missing

Read the AI verdict + X sentiment for $CNXU

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops regenerative biomaterials for wound management, dental, and aesthetic medicine applications.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $CNXU.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $CNXU

Neutral — Develops regenerative biomaterials for wound management, dental, and aesthetic medicine applications; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.0%YTD
+40.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Jun 15, 2026$-0.11$-0.110.0%
Q4 2025Mar 26, 2026$-0.09——
Next earningsWed, Sep 30·consensus EPS $-0.10

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.—Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.—Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.—Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 15.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.005-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyJun 18Purcell Lynn SebastianDirector405.0K sh$628K
+ 4 other (4 exempts) in window

See when $CNXU insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDJul 78-K — Item 7.01: Press release / Reg FD
AI summary

Connexa Sports Technologies disclosed the successful completion of a 12-month PROOF preclinical study for its CXU collagen injectable platform targeting aesthetic indications including GLP-1 weight-loss related skin laxity. The study results support advancing the platform toward IND-enabling studies. The company is positioning CXU to address the rapidly expanding market of patients seeking aesthetic treatments in the context of GLP-1-driven weight loss. Positive preclinical data are an early but necessary step before any human clinical validation can begin.

3New insider — initial holdingsJun 293
AI summary

Andrew Costa joined Conexeu Sciences as a director effective June 15, 2026, holding 50,000 stock options at a $2.30 exercise price (granted February 9, 2026, expiring in 2031). Routine initial Section 16 disclosure for a small-cap biotech director; the option grant is standard board compensation and represents no immediate economic dilution.

3New insider — initial holdingsJun 243
AI summary

April Lynn Burke filed an initial Form 3 as a newly appointed director of Conexeu Sciences Inc. as of June 15, 2026, reporting options to purchase 50,000 shares of common stock at a $2.30 exercise price (granted Feb 9, 2026; vest 25% quarterly over 12 months, expiring Feb 9, 2031). No direct common stock ownership is reported. Administrative — new director at a small-cap biotech; the $2.30 option grant reveals market price context at issuance.

3New insider — initial holdingsJun 233
AI summary

Form 3 filed by A new officer/director (Other (specify below) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5) Date Exercisable Expiration Date Title Amount or Number of Shares Option (right to buy) (1) 02/09/2031 Common Stock 50,000 $ 2.3 D Explanation of Responses: 1. Represents options to purchase shares of common stock that were granted on February 9, 2026 and vest over a 12-month period (25% three, six, nine and twelve months from the date of grant). /s/ Ana Bastiani-Posner 06/23/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 3: SEC 1473 (03-26)) at CNXU on 2026-06-23. This initial statement of beneficial ownership reports the filer's securities holdings as required under Section 16(a). Filing is routine and indicates an insider's initial ownership disclosure following appointment or acquisition of 10%+ stake.

8-KUnregistered equity saleJun 98-K — Item 3.02: Unregistered equity sale
AI summary

Connexa Sports Technologies Inc. (CNXU) reported unregistered sales of equity securities (Item 3.02) in an 8-K filed June 9, 2026. Body unavailable — excerpt cuts off before the specific equity sale terms, share counts, or pricing are disclosed.

3New insider — initial holdingsMay 273
AI summary

Connexa Sports Technologies Inc. (CNXU) filed a Form 3 on May 27, 2026 reporting initial beneficial ownership for a newly appointed director, officer, or 10%+ holder. Body unavailable — excerpt contains only SEC cover-page header.

8-KUnregistered equity saleMay 158-K — Item 3.02: Unregistered equity sale · Item 5.03: Charter amendment
AI summary

Connexa Sports Technologies Inc. (CNXU) reported unregistered sales of equity securities (Item 3.02) and charter/bylaw amendments (Item 5.03) in an 8-K filed May 15, 2026. Body unavailable — excerpt cuts off before the specific equity terms or charter amendment details are disclosed.

3New insider — initial holdingsMay 113
AI summary

Connexa Sports Technologies Inc. (CNXU) filed a Form 3 on May 11, 2026 reporting initial beneficial ownership for a newly designated director, officer, or 10%+ holder. Body unavailable — excerpt contains only SEC cover-page header.

+ 34 other (10 Ds · 10 3s · 5 S-1/As · 2 13Gs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It.prnewswire.com·19d agoThe GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for Itglobenewswire.com·20d agoA $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today's Injectables Were Not Built to Fillglobenewswire.com·27d agoConexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platformglobenewswire.com·39d agoConexeu Sciences: Hanging On The FDA 510(k) Pathway Submissionseekingalpha.com·40d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$REPL$CAPR$IBRX$REGN$AURA$HALO$ALLO$MRNA
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport